MDxHealth vs Exagen
MDXH and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDXH and XGN compare
Exagen grew revenue faster over the last twelve months (20.8% versus 19.8% for MDxHealth).
Exagen keeps more of each dollar of sales as profit, with a net margin of −26.6% compared with −31.1% at MDxHealth.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDXH | XGN |
|---|---|---|
| Size and price | ||
| Market cap | – | $91.1M |
| Share price | $0.149 | $3.76 |
| Change, 1 year | −95.9% | −58.3% |
| Change, 5 years | −98.4% | −65.9% |
| Beta (5Y) | 3.13 | 2.77 |
| Employees | 364 | 220 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.3× |
| P/B | – | 7.5× |
| FCF yield | – | −8.3% |
| Fair value | – | $3.42 |
| Margin of safety | – | −9.9% |
| Growth | ||
| Revenue growth (TTM) | 19.8% | 20.8% (better) |
| Revenue growth, 5Y average | 42.3% (better) | 9.7% |
| Profitability | ||
| Gross margin | 64.5% (better) | 58.6% |
| Operating margin | −13.4% (better) | −18.6% |
| Net margin | −31.1% | −26.6% (better) |
| FCF margin | −3.1% (better) | −10.7% |
| Return on equity | – | −114% |
| Return on invested capital | – | −86.1% |
| Financial health | ||
| Debt / equity | – | 1.87 |
| Interest coverage | −0.6× (better) | −2.6× |
| Current ratio | 1.08 | 3.18 (better) |
| Altman Z-score | – | −6.08 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 32.3% | 34.1% |
| Held by insiders | – | 29.2% |
| Insider net buying, 12 months | $991K (better) | −$769K |
| Short interest, % of float | – | 4.2% |
Go deeper
- MDXH stock overview
- MDXH income statement
- MDXH valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.